NO991701L - HIV og cancer behandling - Google Patents
HIV og cancer behandlingInfo
- Publication number
- NO991701L NO991701L NO991701A NO991701A NO991701L NO 991701 L NO991701 L NO 991701L NO 991701 A NO991701 A NO 991701A NO 991701 A NO991701 A NO 991701A NO 991701 L NO991701 L NO 991701L
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- cancer
- herbicide
- fungicide
- virus
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 239000000417 fungicide Substances 0.000 abstract 5
- 239000004009 herbicide Substances 0.000 abstract 5
- 241000700605 Viruses Species 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000000855 fungicidal effect Effects 0.000 abstract 4
- 230000002363 herbicidal effect Effects 0.000 abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000002538 fungal effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 abstract 2
- 229960004546 thiabendazole Drugs 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 108091092356 cellular DNA Proteins 0.000 abstract 1
- 108091092328 cellular RNA Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 239000004308 thiabendazole Substances 0.000 abstract 1
- 235000010296 thiabendazole Nutrition 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
En metode for å behandle HIV og andre virusinfeksjoner ved administrering av et herbicid eller fungicid eller derivat derav til et dyr eller menneske. Fungicidene eller herbi- cidene kan anvendes sammen med andre behandlinger, f.eks. med AZT- eller protease-inhibitorer for behandling av HIV. Tiabendazol og klorpropam er f.eks. blitt vist til raskt å redusere nivået av virusproduksjon fra cellepopulasjoner som er kronisk infisert med HIV-l og den antivirale effekt opprettholdes med fortsatt forbindelseseksponering. Denne reduksjon av virusproduksjon forekommer ved konsentrasjoner som er ikke-toksiske for vertscellen og som ikke har noen effekt på syntesen av cellulært DNA, RNA og protein. Videre ble kronisk infiserte celler behandlet i forlengede tidsperioder med tiabendazol og klorpropam ikke superinfisert med HIV. En metode for å inhibere vekst av tumorer og cancere i pattedyr som omfatter administrering av et herbicid- eller fungicidderivat er også angitt heri. Fungicidene eller herbicidene kan anvendes sammen med andre behandlinger, f.eks. taxol for behandlingen av bryst-cancer. Forsterkere kan også være inkludert i det herbicide eller fungicide pre- parat. Metoden er særlig effektiv når canceren eller viruset er en animalsk celle som er genetisk modifisert med plante- eller sopp-genetisk material. Et kjemoterapeutisk middel kan også først administreres for å signifikant redusere størrel- sen av canceren og deretter anvendes behandlingen med herbicidet eller_fungicidet. pisse_metpder er særlig effekti- ve når canceren eller viruset er en mutert celle som omfatter plante- eller sopp-genetisk"material.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4672697P | 1997-05-16 | 1997-05-16 | |
| PCT/US1997/021564 WO1998051303A1 (en) | 1997-05-16 | 1997-11-26 | Hiv and cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991701D0 NO991701D0 (no) | 1999-04-09 |
| NO991701L true NO991701L (no) | 2000-01-17 |
Family
ID=21945046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991701A NO991701L (no) | 1997-05-16 | 1999-04-09 | HIV og cancer behandling |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0954309A1 (no) |
| JP (1) | JP2000510156A (no) |
| KR (1) | KR20000049064A (no) |
| CN (1) | CN1254281A (no) |
| AR (1) | AR009968A1 (no) |
| AU (1) | AU7402998A (no) |
| BR (1) | BR9712981A (no) |
| CA (1) | CA2268848A1 (no) |
| CO (1) | CO5070657A1 (no) |
| CZ (1) | CZ124999A3 (no) |
| HU (1) | HUP9904092A3 (no) |
| IL (1) | IL129351A0 (no) |
| NO (1) | NO991701L (no) |
| PE (1) | PE11499A1 (no) |
| PL (1) | PL335160A1 (no) |
| SK (1) | SK46999A3 (no) |
| TR (1) | TR199901530T2 (no) |
| WO (1) | WO1998051303A1 (no) |
| ZA (1) | ZA979095B (no) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
| US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
| US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
| US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
| US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
| US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
| US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
| US6245789B1 (en) * | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
| AU3606600A (en) * | 1999-02-26 | 2000-09-14 | Napro Biotherapeutics, Inc. | Treatment regimen for prostate cancer |
| AU3606700A (en) * | 1999-02-26 | 2000-09-14 | Napro Biotherapeutics, Inc. | Treatment regimen for hormone-sensitive cancers |
| US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
| WO2002015912A1 (en) * | 2000-08-25 | 2002-02-28 | Beth Israel Deaconess Medical Center | Compounds and methods for inhibiting neuronal cell death |
| US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
| US6462062B1 (en) | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
| AU2001292796B2 (en) * | 2000-09-26 | 2005-12-22 | Uaf Technologies And Research Llc | Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| AU2002239395A1 (en) * | 2000-11-01 | 2002-06-03 | The Procter And Gamble Company | Hiv treatment with benzimidazoles |
| JP2004115397A (ja) * | 2002-09-25 | 2004-04-15 | Fuji Photo Film Co Ltd | 血管疾患治療薬を含むリポソーム |
| AU2005313839B2 (en) * | 2004-12-06 | 2010-03-11 | Pitney Pharmaceuticals Pty Limited | Treatment for cancer |
| US20090286838A1 (en) * | 2004-12-06 | 2009-11-19 | Newsouth Innovations Pty Limited | Treatment for cancer |
| US7727967B2 (en) * | 2006-02-24 | 2010-06-01 | Boise State University | Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines |
| WO2009043093A1 (en) * | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| CN101643729B (zh) * | 2008-08-07 | 2011-12-28 | 复旦大学 | 核酸分子nrn1sr22及其在制备抗癌药物中的应用 |
| EP3119768B1 (en) | 2014-03-16 | 2019-07-31 | Hadasit Medical Research Services And Development Ltd. | 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer |
| CN105418711A (zh) * | 2015-11-06 | 2016-03-23 | 山东大学 | 一种α-L-鼠李糖苷酶在制备羟基脲糖苷衍生物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO118000B1 (ro) * | 1993-03-31 | 2002-12-30 | Merck & Co Inc | Metoda pentru tratamentul sida, prevenirea si tratamentul infectiei cu hiv sau inhibarea proteazei hiv si compozitie farmaceutica pentru aplicarea metodei |
| AU714056B2 (en) * | 1995-04-12 | 1999-12-16 | Uaf Technologies And Research Llc | A pharmaceutical composition containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers |
| US5665713A (en) * | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
| US5656615A (en) * | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
| EP0841921A2 (en) * | 1995-08-04 | 1998-05-20 | The Procter & Gamble Company | Use of fluconazole for inhibiting the growth of cancers |
-
1997
- 1997-10-09 PE PE1997000894A patent/PE11499A1/es not_active Application Discontinuation
- 1997-10-10 ZA ZA9709095A patent/ZA979095B/xx unknown
- 1997-10-10 AR ARP970104697A patent/AR009968A1/es unknown
- 1997-11-07 CO CO97065469A patent/CO5070657A1/es unknown
- 1997-11-26 TR TR1999/01530T patent/TR199901530T2/xx unknown
- 1997-11-26 IL IL12935197A patent/IL129351A0/xx unknown
- 1997-11-26 JP JP10522997A patent/JP2000510156A/ja active Pending
- 1997-11-26 HU HU9904092A patent/HUP9904092A3/hu unknown
- 1997-11-26 CZ CZ991249A patent/CZ124999A3/cs unknown
- 1997-11-26 SK SK469-99A patent/SK46999A3/sk unknown
- 1997-11-26 CN CN97182189A patent/CN1254281A/zh active Pending
- 1997-11-26 BR BR9712981-0A patent/BR9712981A/pt unknown
- 1997-11-26 PL PL97335160A patent/PL335160A1/xx unknown
- 1997-11-26 EP EP97949599A patent/EP0954309A1/en not_active Withdrawn
- 1997-11-26 CA CA002268848A patent/CA2268848A1/en not_active Abandoned
- 1997-11-26 AU AU74029/98A patent/AU7402998A/en not_active Abandoned
- 1997-11-26 WO PCT/US1997/021564 patent/WO1998051303A1/en not_active Ceased
- 1997-11-26 KR KR1019990703137A patent/KR20000049064A/ko not_active Ceased
-
1999
- 1999-04-09 NO NO991701A patent/NO991701L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5070657A1 (es) | 2001-08-28 |
| AU7402998A (en) | 1998-12-08 |
| AR009968A1 (es) | 2000-05-17 |
| BR9712981A (pt) | 2000-04-18 |
| JP2000510156A (ja) | 2000-08-08 |
| KR20000049064A (ko) | 2000-07-25 |
| ZA979095B (en) | 1998-05-11 |
| WO1998051303A1 (en) | 1998-11-19 |
| SK46999A3 (en) | 2000-05-16 |
| NO991701D0 (no) | 1999-04-09 |
| HUP9904092A2 (hu) | 2000-04-28 |
| CN1254281A (zh) | 2000-05-24 |
| CA2268848A1 (en) | 1998-11-19 |
| HUP9904092A3 (en) | 2000-07-28 |
| PE11499A1 (es) | 1999-03-01 |
| PL335160A1 (en) | 2000-04-10 |
| TR199901530T2 (xx) | 1999-10-21 |
| EP0954309A1 (en) | 1999-11-10 |
| IL129351A0 (en) | 2000-02-17 |
| CZ124999A3 (cs) | 1999-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991701L (no) | HIV og cancer behandling | |
| DE69122248T2 (de) | Hemmung einer virusinfektion | |
| Hu et al. | Synthesis and biological evaluation of novel coumarin derivatives in rhabdoviral clearance | |
| BG50372A3 (en) | Fungicidal composition a method of combating fungus | |
| NO974696L (no) | Farmasöytisk preparat inneholdende N-klor-fenylkarbamater og N-klorfenyltiokarbamater for inhibering av vekst av virus og cancer | |
| ATE142423T1 (de) | Wässrige dispersionen von sulfonylharnstoffderivaten | |
| KR20170129699A (ko) | 진균성 병원체에 감염된 식물을 처리하는데 효과적인 살진균제 증진제 | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| Maragos et al. | Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice | |
| Reuvers et al. | Potential use of nitrofurans in radiotherapy | |
| EP3115394A1 (en) | Antiviral agent | |
| KR20190032209A (ko) | 식물바이러스 방제용 조성물 및 이의 용도 | |
| CN103039461B (zh) | 一种含有辛菌胺和己唑醇的农药组合物 | |
| JP3222672B2 (ja) | タンパク質合成阻害剤 | |
| Kirk et al. | Efficacy of new active ingredient formulations and new biopesticides for managing Fusarium root rot disease of gladiolus hybrids | |
| Keefer | Broad-Spectrum Anti-Cancer Activity of O 2-Arylated Diazeniumdiolates | |
| CN101946784B (zh) | 银杏内酯b在制备抗烟草花叶病毒药物中的应用 | |
| Anaso et al. | Assessment of loss in yield due to sorghum downy mildew (Peronosclerospora sorghi) of maize in Nigerian guinea savanna | |
| CN102972414B (zh) | 含三唑酮和烯酰吗啉的杀菌组合物 | |
| CN120713119B (zh) | 一种抗植物病毒的农药组合物及其应用 | |
| Purkayastha et al. | A phytoalexin type of reaction in the Botrytis infection of leaves of bean (Vicia faba L.) | |
| CN112040956B (zh) | 包含阿来西定二盐酸盐和五硼酸钠五水合物的组合的化学治疗剂 | |
| Ghosh et al. | Field evaluation of some new insecticides against brown planthopper Nilaparvata lugens (stål) in rice | |
| SU1717051A1 (ru) | Способ борьбы с грибными заболевани ми растений томата | |
| Kumar et al. | Impact of biointensive pest management strategies on yellow stem borer and leaf folder in rice and their effect on the economics of production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |